Page 91

Innovative Health Care Magazine

91 InnovativeHealthMag.com Lawrence Flaherty, M.D., Medical Oncologist, Karmanos Cancer Institute Lawrence Flaherty, M.D., is a world-renowned breast cancer and melanoma oncologist at the Barbara Ann Karmanos Cancer Institute. He is dedicated to serving his patients, and he helps advance cancer treatments to benefit patients here in Michigan and across the globe. Dr. Flaherty is medical director of the Clinical Trials Office at the Karmanos Cancer Institute and a professor of medicine in the Department of Oncology, division of Hematology/ Oncology, at Wayne State University School of Medicine. Recognized nationally and internationally, Dr. Flaherty is an active member of the American Society of Clinical Oncology (ASCO), a consultant to the National Cancer Institute (NCI), and has been voted to the Best Doctors in America list for the past several years. “I’ve been a medical oncologist for 30 years so I’ve seen where we’ve been and how far we’ve come in treating breast cancer,” said Dr. Flaherty. “It’s been a steadfast battle but we are making a difference, especially with the therapies we have available today.” Raising awareness of breast cancer prevention, screening, and advances in breast cancer treatment options have all contributed to improved survival rates. In June 2015, Michigan was among the 20 states in the nation to inform women if their mammogram showed that they have dense breast tissue. Although common, dense breast tissue can make it harder for radiologists to detect an abnormality on the mammogram, since dense breast tissue appears white and cloudy. Notifying women that they have dense breast tissue is another tool to help them be proactive about their own health; they can follow up with their physicians to see if supplemental screening options are necessary, depending on their risk factors. Today, 27 states participate in the breast-density notification. Many of the recent cancer treatments were first made available through the Clinical Trials Program at Karmanos Cancer Institute. “Clinical trials are the engine for progress in the cancer field,” said Dr. Flaherty. “Participation in clinical trials is critical to help advanced-cancer treatments, such as targeted therapies and immunotherapies, setting the next standard of cancer care, used here and around the globe.”


Innovative Health Care Magazine
To see the actual publication please follow the link above